Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Expands Approval of Osimertinib in Lung Cancer

2.

After all, Pulled Myeloma Drug May Help Treat the Illness.

3.

Do I qualify for a cancer clinical trial?

4.

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

5.

Doctors say lung cancer is still the deadliest cancer, but hope is growing


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot